Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population.
Chloe Bryson-CahnAlison M BeielerJeannie D ChanRobert D HarringtonShireesha DhanireddyPublished in: Open forum infectious diseases (2019)
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.
Keyphrases
- staphylococcus aureus
- end stage renal disease
- case report
- newly diagnosed
- ejection fraction
- spinal cord
- escherichia coli
- acute kidney injury
- prognostic factors
- biofilm formation
- peritoneal dialysis
- mesenchymal stem cells
- cystic fibrosis
- methicillin resistant staphylococcus aureus
- bone marrow
- replacement therapy
- smoking cessation
- candida albicans